SLC5A2 and diabetic kidney disease: The combined use of SGLT2 inhibitors and GLP-1 receptor agonists could also reduce proteinuria in patients with diabetic nephropathy, shorten the time to double serum creatinine, and delay the occurrence of end-stage renal disease [95].